Literature DB >> 23429725

Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers.

Irina Esterlis1, Jonas O Hannestad, Evgenia Perkins, Frederic Bois, D Cyril D'Souza, Rachel F Tyndale, John P Seibyl, Dorothy M Hatsukami, Kelly P Cosgrove, Stephanie S O'Malley.   

Abstract

OBJECTIVE: Nicotine promotes smoking partly by binding to β2-containing nicotinic acetylcholine receptors (β2*-nAChRs) in the brain. Smoking one tobacco cigarette results in occupation of 80% of β2*-nAChRs for more than 6 hours. This likely contributes to maintenance of smoking dependence and cessation difficulty. Developing nicotine vaccines could improve treatments. The authors used [123I]5-I-A-85380 single photon emission computed tomography (SPECT) to evaluate the effect of 3'-AmNic-rEPA on the amount of nicotine that binds to β2*-nAChRs in smokers' brain cortical and subcortical regions.
METHOD: Eleven smokers who smoked an average of 19 cigarettes per day, had smoked for 10 years on average, and met criteria for nicotine dependence were given SPECT scans on two days: before and after immunization with 4-400 μg of 3'-AmNic-rEPA. On scan days, three 30-minute baseline emission scans were followed by intravenous administration of nicotine (1.5 mg/70 kg body weight) and up to nine 30-minute emission scans.
RESULTS: β2*-nAChR availability was quantified as VT/fP (total distribution volume divided by free plasma concentration), and nicotine binding was derived by the Lassen plot approach. Immunization led to a 12.5% reduction in nicotine binding. Nicotine bound to β2*-nAChRs correlated positively with nicotine injected before but not after vaccination. The daily number of cigarettes and desire for a cigarette decreased after vaccination.
CONCLUSIONS: This proof-of-concept study demonstrates that immunization with nicotine vaccine can reduce the amount of nicotine binding to β2*-nAChRs and disrupt the relationship between administered nicotine and nicotine available to occupy β2*-nAChRs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429725      PMCID: PMC3738000          DOI: 10.1176/appi.ajp.2012.12060793

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  29 in total

1.  Altered disposition of repeated nicotine doses in rats immunized against nicotine.

Authors:  D E Keyler; Y Hieda; J St Peter; P R Pentel
Journal:  Nicotine Tob Res       Date:  1999-09       Impact factor: 4.244

2.  Investigations using immunization to attenuate the psychoactive effects of nicotine.

Authors:  M Rocío A Carrera; Jon A Ashley; Timothy Z Hoffman; Shigeki Isomura; Peter Wirsching; George F Koob; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2004-02-01       Impact factor: 3.641

3.  Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats.

Authors:  S D Satoskar; D E Keyler; M G LeSage; D E Raphael; C A Ross; P R Pentel
Journal:  Int Immunopharmacol       Date:  2003-07       Impact factor: 4.932

4.  Passive immunization against nicotine attenuates nicotine discrimination.

Authors:  David H Malin; Candice L Alvarado; Katherine S Woodhouse; Hilary Karp; Evelyn Urdiales; Diana Lay; Phillip Appleby; William D Moon; Sofiane Ennifar; Lisa Basham; Ali Fattom
Journal:  Life Sci       Date:  2002-04-26       Impact factor: 5.037

5.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Authors:  Delia Dempsey; Piotr Tutka; Peyton Jacob; Faith Allen; Kerri Schoedel; Rachel F Tyndale; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

6.  A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats.

Authors:  P R Pentel; D H Malin; S Ennifar; Y Hieda; D E Keyler; J R Lake; J R Milstein; L E Basham; R T Coy; J W Moon; R Naso; A Fattom
Journal:  Pharmacol Biochem Behav       Date:  2000-01-01       Impact factor: 3.533

7.  Preclinical development of a vaccine 'against smoking'.

Authors:  E H Cerny; R Lévy; J Mauel; M Mpandi; M Mutter; C Henzelin-Nkubana; L Patiny; G Tuchscherer; T Cerny
Journal:  Onkologie       Date:  2002-10

8.  5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors.

Authors:  A G Mukhin; D Gündisch; A G Horti; A O Koren; G Tamagnan; A S Kimes; J Chambers; D B Vaupel; S L King; M R Picciotto; R B Innis; E D London
Journal:  Mol Pharmacol       Date:  2000-03       Impact factor: 4.436

9.  Tobacco withdrawal symptoms: an experimental analysis.

Authors:  D K Hatsukami; J R Hughes; R W Pickens; D Svikis
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Nicotine conjugate vaccine: is there a right to a smoking future?

Authors:  A Hasman; Søren Holm
Journal:  J Med Ethics       Date:  2004-08       Impact factor: 2.903

View more
  20 in total

Review 1.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

2.  A simple physiologically based pharmacokinetic model evaluating the effect of anti-nicotine antibodies on nicotine disposition in the brains of rats and humans.

Authors:  Kyle Saylor; Chenming Zhang
Journal:  Toxicol Appl Pharmacol       Date:  2016-07-26       Impact factor: 4.219

3.  Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine ([(18)F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates.

Authors:  Frederic Bois; Jean-Dominique Gallezot; Ming-Qiang Zheng; Shu-Fei Lin; Irina Esterlis; Kelly P Cosgrove; Richard E Carson; Yiyun Huang
Journal:  Nucl Med Biol       Date:  2014-08-08       Impact factor: 2.408

Review 4.  Biologic Approaches to Treat Substance-Use Disorders.

Authors:  Phil Skolnick
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

5.  Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats.

Authors:  Michael D Raleigh; Megan Laudenbach; Federico Baruffaldi; Samantha J Peterson; Michaela J Roslawski; Angela K Birnbaum; F Ivy Carroll; Scott P Runyon; Scott Winston; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-03-13       Impact factor: 4.030

Review 6.  New directions in nicotine vaccine design and use.

Authors:  Paul R Pentel; Mark G LeSage
Journal:  Adv Pharmacol       Date:  2014

Review 7.  Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists.

Authors:  Fang Yang; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2019-02-06       Impact factor: 4.530

Review 8.  Tobacco use and cessation for cancer survivors: an overview for clinicians.

Authors:  Maher Karam-Hage; Paul M Cinciripini; Ellen R Gritz
Journal:  CA Cancer J Clin       Date:  2014-05-09       Impact factor: 508.702

Review 9.  Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies.

Authors:  Steven J Simmons; Thomas J Gould
Journal:  J Clin Pharm Ther       Date:  2014-05-14       Impact factor: 2.512

10.  Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice.

Authors:  David C Pryde; Lyn H Jones; David P Gervais; David R Stead; David C Blakemore; Matthew D Selby; Alan D Brown; Jotham W Coe; Matthew Badland; David M Beal; Rebecca Glen; Yvonne Wharton; Gavin J Miller; Phil White; Ningli Zhang; Michelle Benoit; Karen Robertson; James R Merson; Heather L Davis; Michael J McCluskie
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.